ANTX Key Statistics, Chart & Performance
The current stock price of ANTX is 1.1 USD. In the past month the price decreased by -1.79%. In the past year, price decreased by -23.61%.
ANTX Latest News, Press Relases and Analysis
ANTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.94 | 955.13B | ||
| JNJ | JOHNSON & JOHNSON | 19.45 | 486.51B | ||
| MRK | MERCK & CO. INC. | 11.32 | 247.51B | ||
| PFE | PFIZER INC | 8.13 | 148.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.95 | 106.16B | ||
| ZTS | ZOETIS INC | 18.71 | 52.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 22.93B | ||
| VTRS | VIATRIS INC | 4.69 | 12.59B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.81 | 10.88B | ||
| CORT | CORCEPT THERAPEUTICS INC | 97.85 | 9.06B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.52B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.23B |
Related stock screener links
About ANTX
Company Profile
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California and currently employs 22 full-time employees. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
Company Info
AN2 THERAPEUTICS INC
1800 El Camino Real, Suite D
Menlo Park CALIFORNIA 90501 US
CEO: Robert Corrigan
Employees: 22
Phone: 16503319090
AN2 THERAPEUTICS INC / ANTX FAQ
What does ANTX do?
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California and currently employs 22 full-time employees. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
Can you provide the latest stock price for AN2 THERAPEUTICS INC?
The current stock price of ANTX is 1.1 USD. The price increased by 3.29% in the last trading session.
Does AN2 THERAPEUTICS INC pay dividends?
ANTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANTX stock?
ANTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for ANTX stock?
8 analysts have analysed ANTX and the average price target is 1.53 USD. This implies a price increase of 39.09% is expected in the next year compared to the current price of 1.1.
What is AN2 THERAPEUTICS INC worth?
AN2 THERAPEUTICS INC (ANTX) has a market capitalization of 30.14M USD. This makes ANTX a Nano Cap stock.
What is the outstanding short interest for AN2 THERAPEUTICS INC?
The outstanding short interest for AN2 THERAPEUTICS INC (ANTX) is 0.23% of its float.
ANTX Technical Analysis
ANTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANTX. While ANTX has a great health rating, there are worries on its profitability.
ANTX Financial Highlights
Over the last trailing twelve months ANTX reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 42.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.55% | ||
| ROE | -56.29% | ||
| Debt/Equity | 0 |
ANTX Forecast & Estimates
8 analysts have analysed ANTX and the average price target is 1.53 USD. This implies a price increase of 39.09% is expected in the next year compared to the current price of 1.1.